[Skip to Navigation]
May 1975

Plasma Albumin Concentration and Diphenylhydantoin Binding in Man

Author Affiliations

From the Department of Neurology, University of California School of Medicine, San Francisco. Dr. Porter is now at the Applied Neurologic Research Branch of the National Institutes of Health, Bethesda, Md.

Arch Neurol. 1975;32(5):298-303. doi:10.1001/archneur.1975.00490470042005

The plasma protein binding of diphenylhydantoin sodium wad determined In 26 patients who had been taking diphenylhydantoin regularly for more than two weeks. The free (unbound) diphenylhydantoin level was found to vary from 5.8% to 12.6% of the total drug concentration. This range of variation may be clinically important, if it can be established that the binding of diphenylhydantoin to plasma proteins limits entry of the drug into the brain. The binding of diphenylhydantoin was directly proportional to the plasma albumin concentration, which thus appeared to be the most important determinant of diphenlhydantoin binding. Diphenylhydantoin binding was independent of the plasma concentration of the drug in the usual therapeutic range. In vitro studies showed little effect by phenobarbital sodium or penicillin G; therapeutic levels of acetylsalicylic acid, however, increased free diphenylhydantoin by nearly 50%.

Add or change institution